Item 16. FORM 10-K SUMMARY

3K characters. Original on sec.gov · Markdown

Item 16. FORM 10-K SUMMARY

None.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, West Pharmaceutical Services, Inc. has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

WEST PHARMACEUTICAL SERVICES, INC.

(Registrant)

By: /s/ Bernard J. Birkett

Bernard J. Birkett

Senior Vice President, Chief Financial and Operations Officer

February 20, 2024

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of West Pharmaceutical Services, Inc. and in the capacities and on the dates indicated.


Signature	Title	Date
/s/ Eric M. Green	President, Chief Executive Officer and Chair of the Board	February 20, 2024
Eric M. Green	(Principal Executive Officer)

/s/ Bernard J. Birkett	Senior Vice President, Chief Financial and Operations Officer	February 20, 2024
Bernard J. Birkett	(Principal Financial Officer)

/s/ Chad R. Winters	Vice President, Chief Accounting Officer and Corporate Controller	February 20, 2024
Chad R. Winters	(Principal Accounting Officer)

/s/ Mark A. Buthman	Director	February 20, 2024
Mark A. Buthman

/s/ William F. Feehery, Ph.D.	Director	February 20, 2024
William F. Feehery, Ph.D.

/s/ Robert F. Friel	Director	February 20, 2024
Robert F. Friel

/s/ Thomas W. Hofmann	Director	February 20, 2024
Thomas W. Hofmann

/s/ Molly E. Joseph	Director	February 20, 2024
Molly E. Joseph

/s/ Deborah L.V. Keller	Director	February 20, 2024
Deborah L.V. Keller

/s/ Myla P. Lai-Goldman, M.D.	Director	February 20, 2024
Myla P. Lai-Goldman, M.D.

/s/ Douglas A. Michels	Director	February 20, 2024
Douglas A. Michels

/s/ Paolo Pucci	Director	February 20, 2024
Paolo Pucci

/s/ Stephen Lockhart, Ph.D.	Director	February 20, 2024
Stephen Lockhart, Ph.D.

Previous: Item 15. EXHIBITS AND FINANCIAL STATEMENT SCHEDULES